223 related articles for article (PubMed ID: 32751071)
41. Thymidylate synthase and drug resistance.
Peters GJ; van der Wilt CL; van Triest B; Codacci-Pisanelli G; Johnston PG; van Groeningen CJ; Pinedo HM
Eur J Cancer; 1995; 31A(7-8):1299-305. PubMed ID: 7577040
[TBL] [Abstract][Full Text] [Related]
42. Mechanisms of acquired resistance to modulation of 5-fluorouracil by leucovorin in HCT-8 human ileocecal carcinoma cells.
Lu K; McGuire JJ; Slocum HK; Rustum YM
Biochem Pharmacol; 1997 Mar; 53(5):689-96. PubMed ID: 9113088
[TBL] [Abstract][Full Text] [Related]
43. Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil.
Copur S; Aiba K; Drake JC; Allegra CJ; Chu E
Biochem Pharmacol; 1995 May; 49(10):1419-26. PubMed ID: 7763285
[TBL] [Abstract][Full Text] [Related]
44. DNA mismatch repair (MMR)-dependent 5-fluorouracil cytotoxicity and the potential for new therapeutic targets.
Li LS; Morales JC; Veigl M; Sedwick D; Greer S; Meyers M; Wagner M; Fishel R; Boothman DA
Br J Pharmacol; 2009 Oct; 158(3):679-92. PubMed ID: 19775280
[TBL] [Abstract][Full Text] [Related]
45. Roles of thymidylate synthase and dihydropyrimidine dehydrogenase in tumor progression and sensitivity to 5-fluorouracil in human gastric cancer.
Terashima M; Irinoda T; Fujiwara H; Nakaya T; Takagane A; Abe K; Yonezawa H; Oyama K; Inaba T; Saito K; Takechi T; Fukushima M
Anticancer Res; 2002; 22(2A):761-8. PubMed ID: 12014648
[TBL] [Abstract][Full Text] [Related]
46. [5-fluorouracil and dihydropyrimidine dehydrogenase].
Kubota T
Gan To Kagaku Ryoho; 2001 Apr; 28(4):433-9. PubMed ID: 11329775
[TBL] [Abstract][Full Text] [Related]
47. [Recent advance in chemotherapy for advanced colorectal cancer].
Aiba K
Gan To Kagaku Ryoho; 1996 Apr; 23(5):535-48. PubMed ID: 8678510
[TBL] [Abstract][Full Text] [Related]
48. Thymidylate synthetase (TS) genotype and TS/dihydropyrimidine dehydrogenase mRNA level as an indicator in determining chemosensitivity to 5-fluorouracil in advanced gastric carcinoma.
Toriumi F; Kubota T; Saikawa Y; Yoshida M; Otani Y; Watanabe M; Kumai K; Kitajima M
Anticancer Res; 2004; 24(4):2455-63. PubMed ID: 15330198
[TBL] [Abstract][Full Text] [Related]
49. Overexpression of thymidylate synthase mediates desensitization for 5-fluorouracil of tumor cells.
Saga Y; Suzuki M; Mizukami H; Kohno T; Takei Y; Fukushima M; Ozawa K
Int J Cancer; 2003 Sep; 106(3):324-6. PubMed ID: 12845668
[TBL] [Abstract][Full Text] [Related]
50. Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks.
Wang W; McLeod HL; Cassidy J; Collie-Duguid ES
Cancer Chemother Pharmacol; 2007 May; 59(6):839-45. PubMed ID: 17119966
[TBL] [Abstract][Full Text] [Related]
51. Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines.
Chu E; Drake JC; Koeller DM; Zinn S; Jamis-Dow CA; Yeh GC; Allegra CJ
Mol Pharmacol; 1991 Feb; 39(2):136-43. PubMed ID: 1704999
[TBL] [Abstract][Full Text] [Related]
52. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism.
Peters GJ; Backus HH; Freemantle S; van Triest B; Codacci-Pisanelli G; van der Wilt CL; Smid K; Lunec J; Calvert AH; Marsh S; McLeod HL; Bloemena E; Meijer S; Jansen G; van Groeningen CJ; Pinedo HM
Biochim Biophys Acta; 2002 Jul; 1587(2-3):194-205. PubMed ID: 12084461
[TBL] [Abstract][Full Text] [Related]
53. Correlation of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase with sensitivity of gastrointestinal cancer cells to 5-fluorouracil and 5-fluoro-2'-deoxyuridine.
Ma T; Zhu ZG; Ji YB; Zhang Y; Yu YY; Liu BY; Yin HR; Lin YZ
World J Gastroenterol; 2004 Jan; 10(2):172-6. PubMed ID: 14716816
[TBL] [Abstract][Full Text] [Related]
54. Polymorphic tandem repeat sequences of the thymidylate synthase gene correlates with cellular-based sensitivity to fluoropyrimidine antitumor agents.
Yawata A; Kim SR; Miyajima A; Kubo T; Ishida S; Saito Y; Nakajima Y; Katori N; Matsumoto Y; Fukuoka M; Ohno Y; Ozawa S; Sawada J
Cancer Chemother Pharmacol; 2005 Nov; 56(5):465-72. PubMed ID: 15918040
[TBL] [Abstract][Full Text] [Related]
55. Differences in the induction of DNA damage, cell cycle arrest, and cell death by 5-fluorouracil and antifolates.
Backus HH; Pinedo HM; Wouters D; Kuiper CM; Jansen G; van Groeningen CJ; Peters GJ
Oncol Res; 2000; 12(5):231-9. PubMed ID: 11417748
[TBL] [Abstract][Full Text] [Related]
56. Benzylacyclouridine enhances 5-fluorouracil cytotoxicity against human prostate cancer cell lines.
Yee LK; Chu E; Pan BC; Chu SH; Chen TM; Lipsky MH; Chu MY; Calabresi P
Pharmacology; 1998 Feb; 56(2):80-91. PubMed ID: 9494066
[TBL] [Abstract][Full Text] [Related]
57. Resistance of a human ovarian cancer line to 5-fluorouracil associated with decreased levels of 5-fluorouracil in DNA.
Chu E; Lai GM; Zinn S; Allegra CJ
Mol Pharmacol; 1990 Sep; 38(3):410-7. PubMed ID: 2402230
[TBL] [Abstract][Full Text] [Related]
58. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
[TBL] [Abstract][Full Text] [Related]
59. 5-fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine.
Correale P; Del Vecchio MT; Di Genova G; Savellini GG; La Placa M; Terrosi C; Vestri M; Urso R; Lemonnier F; Aquino A; Bonmassar E; Giorgi G; Francini G; Cusi MG
J Natl Cancer Inst; 2005 Oct; 97(19):1437-45. PubMed ID: 16204693
[TBL] [Abstract][Full Text] [Related]
60. Differential effects of two fluorouracil administration regimens for colorectal cancer.
Matsusaka S; Yamasaki H; Kitayama Y; Okada T; Maeda S
Oncol Rep; 2003; 10(1):109-13. PubMed ID: 12469154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
